DCTH Stock Analysis
DC
Uncovered
Delcath Systems Inc is uncovered by Eyestock quantitative analysis.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Low score
Delcath Systems, Inc. is an oncology company, which focuses on the treatment of primary and metastatic liver cancers. The company is headquartered in New York City, New York and currently employs 45 full-time employees. The company went IPO on 2000-10-19. The firm's lead product candidate, the HEPZATO KIT (melphalan hydrochloride for injection/hepatic delivery system) is a drug/device combination product. HEPZATO KIT is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. In Europe, its commercial product is a medical device having the same device components as the HEZPATO KIT but without the melphalan hydrochloride, is designated as a Class III medical device, and is sold under the trade name CHEMOSAT Hepatic Delivery System for Melphalan (CHEMOSAT), where it is being used at various medical centers to treat a range of cancers of the liver. In the United States, HEPZATO KIT is considered a combination drug and device product. The firm's product administers concentrated regional chemotherapy to the liver.